Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaRobert Chen|Journal of Clinical Oncology|2017Cited by 976
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Haesook T. Kim et al.|Journal of Clinical Oncology|2016Cited by 187